Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 91.39M
March 31, 2026 90.89M
December 31, 2025 90.48M
September 30, 2025 90.28M
June 30, 2025 90.25M
March 31, 2025 82.84M
December 31, 2024 81.85M
September 30, 2024 81.38M
June 30, 2024 70.91M
March 31, 2024 70.55M
December 31, 2023 69.90M
September 30, 2023 69.83M
June 30, 2023 69.80M
March 31, 2023 66.70M
December 31, 2022 65.81M
September 30, 2022 65.61M
June 30, 2022 65.49M
March 31, 2022 65.30M
December 31, 2021 65.11M
September 30, 2021 64.83M
June 30, 2021 64.62M
March 31, 2021 64.49M
December 31, 2020 64.28M
September 30, 2020 59.23M
June 30, 2020 59.12M
Date Value
March 31, 2020 59.02M
December 31, 2019 58.88M
September 30, 2019 58.39M
June 30, 2019 57.94M
March 31, 2019 54.54M
December 31, 2018 54.06M
September 30, 2018 53.94M
June 30, 2018 53.51M
March 31, 2018 48.92M
December 31, 2017 48.36M
September 30, 2017 48.34M
June 30, 2017 48.32M
March 31, 2017 41.84M
December 31, 2016 41.26M
September 30, 2016 41.22M
June 30, 2016 41.17M
March 31, 2016 40.79M
December 31, 2015 40.34M
September 30, 2015 40.30M
June 30, 2015 40.25M
March 31, 2015 39.87M
December 31, 2014 39.56M
September 30, 2014 39.51M
June 30, 2014 38.86M
March 31, 2014 38.66M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Lifecore Biomedical, Inc. 37.70M
Quanterix Corp. 47.14M
Frontage Holdings Corp. --
Repligen Corp. 56.43M
Bio-Techne Corp. 156.10M